| Staff Scientists and Clinicians
José A. Apud, M.D., Ph.D. |
|
|
Dr. José A. Apud is Clinical Director for the Schizophrenia Research Program, Clinical Brain Disorders Branch of the Intramural Research Program, National Institute of Mental Health, National Institutes of Health in Bethesda, Maryland. He received his M.D. at the University of Tucumán, Argentina and his Ph.D. at the University of Buenos Aires. He received a degree of Specialist in Pharmacology and a degree in Experimental Endocrinology at the University of Milan, Italy. He was Professor of Pharmacology at the University of Buenos Aires and Visiting Professor of Pharmacology at Georgetown University. At present, he is Clinical Professor of Psychiatry at George Washington University and Adjunct Professor of Neuroscience at Georgetown University in Washington D.C. He initiated his residency in Psychiatry at the Psychiatry Residency program at St. Elizabeth’s Hospital in Washington D.C. and completed his training in the PGY4/Fellowship combined program at the Neuropsychiatric Branch of the Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Washington DC. He is Board Certified in Psychiatry. |
Research Interests |
Dr. Apud’s present interest is to study the pharmacogenetics of cognition in schizophrenia based on the pharmacological response to drugs with ability to increase dopaminergic function in individuals with different genotypes for the enzyme COMT. This model includes paradigms aiming at blocking dopamine degradation (COMT inhibitors) or reducing the reuptake of dopamine (Modafinil, Atomoxetine) in the human dorsolateral prefrontal cortex. |
Representative Selected Recent Publications: |
- JA Apud, Weinberger Daniel: Treatment of Cognitive Deficits Associated with Schizophrenia: Potential Role of COMT Inhibitors. CNS Drugs, 21(7):535-57, 2007.
- JA Apud, Mattay, A, Chen, B, Kolachana, J. Callicott, R. Rasetti, G. Alce,, J. Iudicello, N. Akbar, M. F. Egan, T. E. Goldberg, D. R. Weinberger: Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology, May;32(5):1011-20, 2007.
- JA Apud, Weinberger DR: Pharmacogenetic tools for the development of "target-oriented" cognitive enhancing drugs NeuroRX, 3:106-116, 2006.
- J. Chen, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud JA, Egan MF, Kleinman JE, Weinberger DR: Functional Analysis of Genetic Variation in Catechol-O-Methyltransferase (COMT): Effects on mRNA, Protein, and Enzyme Activity in Postmortem Human Brain Am J Hum Genet., Nov;75(5):807-21, 2004.
- T.W. Weickert, T. Goldberg, A. Mishara, J.A. Apud, M.F. Egan, D.R. Weinberger: COMT Val 108/158 Met genotype predicts antipsychotic medication response in working memory performance of patients with schizophrenia Biol Psychiatry., Nov 1;56(9):677-82, 2004.
- M.F. Egan, Daniel R. Weinberger, Terry E. Goldberg: G72 genotype predicts cognitive response to treatment with antipsychotic medications Biol Psychiatry., Nov 1;56(9):677-82, 2004.
|
|
|
|